TY - JOUR
T1 - IgE Activates Monocytes from Cancer Patients to Acquire a Pro-Inflammatory Phenotype
AU - Nakamura, Mano
AU - Souri, Elmira Amiri
AU - Osborn, Gabriel
AU - Laddach, Roman
AU - Chauhan, Jitesh
AU - Stavraka, Chara
AU - Lombardi, Sara
AU - Black, Anna
AU - Khiabany, Atousa
AU - Khair, Duaa O
AU - Figini, Mariangela
AU - Winship, Anna
AU - Ghosh, Sharmistha
AU - Montes, Ana
AU - Spicer, James F
AU - Bax, Heather J
AU - Josephs, Debra H
AU - Lacy, Katie E
AU - Tsoka, Sophia
AU - Karagiannis, Sophia N
PY - 2020/11/15
Y1 - 2020/11/15
N2 - IgE contributes to host-protective functions in parasitic and bacterial infections, often by monocyte and macrophage recruitment. We previously reported that monocytes contribute to tumour antigen-specific IgE-mediated tumour growth restriction in rodent models. Here, we investigate the impact of IgE stimulation on monocyte response, cellular signalling, secretory and tumour killing functions. IgE cross-linking on human monocytes with polyclonal antibodies to mimic formation of immune complexes induced upregulation of co-stimulatory (CD40, CD80, CD86), and reduced expression of regulatory (CD163, CD206, MerTK) monocyte markers. Cross-linking and tumour antigen-specific IgE antibody-dependent cellular cytotoxicity (ADCC) of cancer cells by cancer patient-derived monocytes triggered release of pro-inflammatory mediators (TNFα, MCP-1, IL-10, CXCL-10, IL-1β, IL-6, IL-23). High intratumoural gene expression of these mediators was associated with favourable five-year overall survival in ovarian cancer. IgE cross-linking of trimeric FcεRI on monocytes stimulated the phosphorylation of intracellular protein kinases widely reported to be downstream of mast cell and basophil tetrameric FcεRI signalling. These included recently-identified FcεRI pathway kinases Fgr, STAT5, Yes and Lck, which we now associate with monocytes. Overall, anti-tumour IgE can potentiate pro-inflammatory signals, and prime tumour cell killing by human monocytes. These findings will inform the development of IgE monoclonal antibody therapies for cancer.
AB - IgE contributes to host-protective functions in parasitic and bacterial infections, often by monocyte and macrophage recruitment. We previously reported that monocytes contribute to tumour antigen-specific IgE-mediated tumour growth restriction in rodent models. Here, we investigate the impact of IgE stimulation on monocyte response, cellular signalling, secretory and tumour killing functions. IgE cross-linking on human monocytes with polyclonal antibodies to mimic formation of immune complexes induced upregulation of co-stimulatory (CD40, CD80, CD86), and reduced expression of regulatory (CD163, CD206, MerTK) monocyte markers. Cross-linking and tumour antigen-specific IgE antibody-dependent cellular cytotoxicity (ADCC) of cancer cells by cancer patient-derived monocytes triggered release of pro-inflammatory mediators (TNFα, MCP-1, IL-10, CXCL-10, IL-1β, IL-6, IL-23). High intratumoural gene expression of these mediators was associated with favourable five-year overall survival in ovarian cancer. IgE cross-linking of trimeric FcεRI on monocytes stimulated the phosphorylation of intracellular protein kinases widely reported to be downstream of mast cell and basophil tetrameric FcεRI signalling. These included recently-identified FcεRI pathway kinases Fgr, STAT5, Yes and Lck, which we now associate with monocytes. Overall, anti-tumour IgE can potentiate pro-inflammatory signals, and prime tumour cell killing by human monocytes. These findings will inform the development of IgE monoclonal antibody therapies for cancer.
KW - AllergoOncology
KW - Cancer
KW - Cancer immunotherapy
KW - Cross-linking
KW - Cytotoxicity
KW - FcεRI
KW - IgE
KW - Monocytes
UR - http://www.scopus.com/inward/record.url?scp=85096137304&partnerID=8YFLogxK
U2 - 10.3390/cancers12113376
DO - 10.3390/cancers12113376
M3 - Article
C2 - 33203088
SN - 2072-6694
VL - 12
SP - 1
EP - 19
JO - Cancers
JF - Cancers
IS - 11
M1 - 3376
ER -